人福医药：公司始终专注于医药主业的发展

Core Viewpoint - The company is focused on its core pharmaceutical business and is actively optimizing its asset structure while enhancing its competitive advantages in specific segments [1] Financial Performance - In the first three quarters of 2025, the company achieved a net profit attributable to shareholders of 1.689 billion yuan, representing a year-on-year growth of 6.22% [1] - As of the end of the third quarter of 2025, the company's asset-liability ratio decreased to 40.53%, indicating continuous improvement in its asset structure [1]